RxDoctor Payments Data

Ruth Wintz, MD

Nephrology · Houston, TXNPI 1891728168

Payments from drug & device makers

$12,955in general payments, 2019–2025

Across 267 payments — averaging $48.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$5K
  • Otsuka America Pharmaceutical, Inc.$4K
  • Vifor Pharma, Inc.$708
  • OPKO Pharmaceuticals, LLC$559
  • AstraZeneca$458
  • GSK$235
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$3,15224%
  • Speaking & faculty fees$4,28533%
  • Travel & lodging$2012%
  • Food & beverage$4,89838%
  • Education$4203%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,955 in reported general payments places this provider in the 80th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$314,547
Medicare patients
282
Services billed
4,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$140,870
FarxigaDapagliflozin Propanediol78$82,065
KerendiaFinerenone20$27,502
OzempicSemaglutide15$25,312
VeltassaPatiromer Calcium Sorbitex23$24,683
Cinacalcet Hcl28$3,931
Potassium Chloride68$2,906
Calcitriol109$2,792
SpsSodium Polystyrene Sulfon/Sorb13$2,590
Tacrolimus13$2,418
Torsemide82$2,362
Losartan Potassium113$1,398
Nifedipine ErNifedipine23$1,196
Atorvastatin Calcium121$961
Carvedilol85$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$458$82,06578 claims
BayerKerendia$162$27,50220 claims
Novo NordiskOzempic$55$25,31215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →